secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001193125-21-264493
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50
--------------------------------------------------------------------------------

- Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.
- Secondary endpoint EASI-90: 27.6% active vs 20.5% placebo (p=0.3075); IGA success: 38.2% vs 29.5% (p=0.2599).
- Company will not continue development of FB-401; plans to provide future update on company direction.
- Cash and cash equivalents of $50.8 million as of June 30, 2021.
- Previously scheduled September 7 conference call canceled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/0001193125-21-264493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/d88078d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-264493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer